FindTrial
Sign In

Psychiatric side effects of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Remmers (VEGF-R-TKI)

Psychiatric side effects of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Remmers (VEGF-R-TKI) - Psychiatric Side Effects of VEGF-TKI

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON30546
Enrollment
99
Registered
2007-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric side effects

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Treatment with VEGF-Receptor Tyrosine Kinase Inhibitors (VEGF-R-TKI)

Exclusion criteria

Exclusion criteria: N.A.

Design outcomes

Primary

MeasureTime frame
Psychiatric side effects: observed frequency, symptomatology, severity, relationship with VEGF-R-TKI—

Secondary

MeasureTime frame
None applicable—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)